<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00508625</url>
  </required_header>
  <id_info>
    <org_study_id>20050190</org_study_id>
    <nct_id>NCT00508625</nct_id>
  </id_info>
  <brief_title>A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab</brief_title>
  <official_title>A Multicenter, Open Label, Randomized Study of AMG 951 in Subjects With Previously Untreated Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy With or Without Bevacizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      This is a phase 2 multicenter, open label, randomized study of AMG 951 (rhApo2L/TRAIL) in&#xD;
      subjects with previously untreated stage IIIb/IV NSCLC treated with chemotherapy with or&#xD;
      without bevacizumab.&#xD;
&#xD;
      Subjects will be assigned to a set of treatment groups depending on their eligibility to&#xD;
      receive bevacizumab. Subjects with squamous NSCLC and/or CNS metastases will not be eligible&#xD;
      to receive bevacizumab and will be assigned to either cohort A or B (provided all other&#xD;
      eligibility criteria are met). Subjects who are eligible to receive bevacizumab will be&#xD;
      assigned to cohort C, D or E. Cohorts are defined as follows:&#xD;
&#xD;
      Subjects with squamous NSCLC or CNS mets:&#xD;
&#xD;
      Cohort A: Chemotherapy alone Cohort B: Chemotherapy plus 8 mg/kg AMG 951 for 5 days&#xD;
&#xD;
      Subjects without squamous NSCLC and without CNS mets:&#xD;
&#xD;
      Cohort C: Chemotherapy and bevacizumab Cohort D: Chemotherapy, bevacizumab plus 8 mg/kg AMG&#xD;
      951 for 5 days Cohort E: Chemotherapy, bevacizumab plus up to 20 mg/kg AMG 951 for 2 days&#xD;
      Approximately forty subjects will be recruited to each cohort.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (CR and PR) by modified RECIST</measure>
    <time_frame>Until disease progression, drug intolerability or withdrawal of consent</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Until disease progression, drug intolerability or withdrawal of consent</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>Until disease progression, drug intolerability or withdrawal of consent</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Until disease progression, drug intolerability or withdrawal of consent</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Until disease progression, drug intolerability or withdrawal of consent</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (complete, partial or stable response)</measure>
    <time_frame>Until disease progression, drug intolerability or withdrawal of consent</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Until disease progression, drug intolerability or withdrawal of consent</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">213</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 of each 21 day cycle until disease progression, study drug intolerability or withdrawal of consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 and AMG 951 (rhApo2L/TRAIL) (20mg/kg) on days 1-2 per 21 day cycle until disease progression, study drug intolerability or withdrawal of consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus AMG 951 (rhApo2L/TRAIL) (8mg/kg) for 5 days per 21 days cycle until disease progression, study drug intolerability or withdrawal of consent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>40 subjects will receive up to 6 cycles of Carboplatin (AUC = 6.0mg/ml.min) and Paclitaxel (200mg/m2) only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 subjects will receive up to 6 cycles of carboplatin (AUC=6.0mg/ml.min) and paclitaxel (200mg/m2) on day 1 of each 21 day cycle plus Bevacizumab (15mg/kg) on day 1 and AMG 951 (rhApo2L/TRAIL) (8mg/kg) on days 1-5 per 21 day cycle until disease progression, study drug intolerability or withdrawal of consent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 951 (rhApo2L/TRAIL)</intervention_name>
    <description>AMG 951 is recombinant human Apo2Ligand/Tumor necrosis factor related apoptosis inducing ligand (rhApo2L/TRAIL) that triggers apoptosis through activation of death receptor 4 (DR4) and death receptor 5 (DR5).</description>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
    <other_name>Dulanermin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab is a recombinant humanized version of a murine antibody to vascular endothelial growth factor (VEGF).</description>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Standard platinum based chemotherapy</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Standard taxane chemotherapy</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed Non-Small Cell Lung Cancer (NSCLC). Mixed&#xD;
             tumors will be categorized by the predominant cell type unless small cell elements are&#xD;
             present in which case the patient is ineligible. Cytologic or histologic elements can&#xD;
             be established on metastatic tumor aspirates or biopsy.&#xD;
&#xD;
          -  Subjects must have advanced NSCLC defined as stage IIIb with malignant pleural&#xD;
             effusion or Stage IV or recurrent disease. Subjects with unmeasurable but evaluable&#xD;
             disease can be included in the phase 1b study, but disease must be measurable to be&#xD;
             included in the phase 2 study&#xD;
&#xD;
          -  Planning to receive up to 6 cycles of chemotherapy&#xD;
&#xD;
          -  ECOG performance status of 0 or 1&#xD;
&#xD;
          -  Life expectancy greater than 3 months&#xD;
&#xD;
          -  ≥18 years old&#xD;
&#xD;
          -  Subjects must sign and date a written Independent Ethics Committee (IEC)-approved&#xD;
             Informed Consent Form&#xD;
&#xD;
          -  INR ≤ 1.2 and PTT ≤ ULN within 1 week prior to enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Disease Related&#xD;
&#xD;
          -  Prior malignancy other than NSCLC (except in situ basal cell carcinoma or in situ&#xD;
             cervical cancer), unless have been treated with curative intent with no evidence of&#xD;
             disease for &gt; 3 years&#xD;
&#xD;
          -  Untreated or unstable central nervous system (CNS) metastases. Subjects with treated&#xD;
             and stably controlled CNS metastases are eligible for cohorts A and B of the phase 2&#xD;
             part of the study if definitive therapy has been administered (surgery and/or&#xD;
             radiation therapy), there is no planned treatment for brain metastases, and the&#xD;
             subject is clinically stable and is off corticosteroids or on a stable dose of&#xD;
             corticosteroids for at least 2 weeks prior to enrollment&#xD;
&#xD;
          -  Myocardial infarction, or unstable or uncontrolled disease or condition related to or&#xD;
             impacting cardiac function (e.g., unstable angina, congestive heart failure [New York&#xD;
             Heart Association &gt; class II]) within 1 year of enrollment&#xD;
&#xD;
          -  Uncontrolled hypertension defined as: systolic blood pressure &gt; 150 mm Hg OR diastolic&#xD;
             blood pressure &gt; 100 mm Hg (antihypertensive therapy to achieve these parameters is&#xD;
             allowable)&#xD;
&#xD;
          -  History of arterial thrombosis, pulmonary embolus, deep vein thrombosis or hemorrhagic&#xD;
             disorders within 1 year of enrollment&#xD;
&#xD;
          -  Recent major surgical procedure within 28 days of enrollment&#xD;
&#xD;
          -  Subjects must not have serious non-healing wound ulcer, or bone fracture within 21&#xD;
             days prior to enrollment&#xD;
&#xD;
          -  Persistent history of gross hemoptysis (defined as bright red blood of a ½ teaspoon or&#xD;
             more) related to subject's NSCLC&#xD;
&#xD;
          -  Known (documented in medical notes) HIV infection&#xD;
&#xD;
          -  Active infection on day of enrollment&#xD;
&#xD;
          -  Known to be hepatitis C positive OR hepatitis B surface antigen positive&#xD;
&#xD;
          -  Subjects with Gilbert's syndrome&#xD;
&#xD;
        Laboratory&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt; 1.5 x 10*9 /L (without granulocyte-colony&#xD;
             stimulating factor support within 2 weeks of enrollment)&#xD;
&#xD;
          -  Platelet count &lt; 100 x 10*9 /L (without transfusion within 2 weeks of enrollment)&#xD;
&#xD;
          -  Hemoglobin &lt; 9 g/dL (subjects may be transfused or receive erythropoietic treatment to&#xD;
             meet criterion)&#xD;
&#xD;
          -  Urine protein quantitative value of &gt; 1+ on dipstick or &gt; 30 mg/dL in urinalysis. If&#xD;
             quantitative protein is &lt; 500 mg in 24-hour urine collection then subject can be&#xD;
             included&#xD;
&#xD;
          -  Significant liver dysfunction as defined by aspartate aminotransferase (AST) or&#xD;
             alanine aminotransferase (ALT) &gt; 2.5 x upper limits of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase &gt; 2.5 x ULN, or alkaline phosphatase &gt; 5 x ULN in the presence of&#xD;
             bone or liver metastasis&#xD;
&#xD;
          -  Total bilirubin &gt; 1.5 x ULN&#xD;
&#xD;
          -  Calculated creatinine clearance &lt; 50 mL/min.&#xD;
&#xD;
          -  Hypercalcemia (serum calcium &gt; 12.0 mg/dL or symptomatic)&#xD;
&#xD;
        Medications&#xD;
&#xD;
          -  Prior chemotherapy (except for adjuvant chemotherapy, provided the last dose of&#xD;
             adjuvant therapy was received at least one year prior to enrollment), hormonal&#xD;
             therapy, radiotherapy (except palliative radiotherapy for bone metastases or radiation&#xD;
             therapy for CNS metastases) or immunotherapy for treatment of advanced NSCLC&#xD;
&#xD;
          -  Prior drug treatment or therapy with investigational agents for NSCLC&#xD;
&#xD;
          -  Therapeutic anticoagulation treatment. Prophylactic anticoagulation of venous access&#xD;
             devices (eg, with low-dose warfarin [1-2mg/day] or low-dose heparin) is allowed&#xD;
             providing INR ≤ 1.2 and PTT is ≤ ULN within 1 week prior to enrollment&#xD;
&#xD;
          -  Chronic daily treatment with aspirin (&gt; 325 mg/day) or non-steroidal anti-inflammatory&#xD;
             agents known to inhibit platelet function. Treatment with dipyridamole, ticlopidine,&#xD;
             clopidogrel and/or cilostazol is also not allowed.&#xD;
&#xD;
        General Exclusions&#xD;
&#xD;
          -  Participation in clinical trials or undergoing other investigational procedures within&#xD;
             30 days before study enrollment&#xD;
&#xD;
          -  Subject is evidently pregnant (e.g. positive HCG test) or is breast feeding&#xD;
&#xD;
          -  Woman or man with partner of childbearing potential not consenting to use adequate&#xD;
             contraceptive precautions i.e. double barrier contraceptive methods (eg diaphragm plus&#xD;
             condom), or abstinence during the course of the study and for 6 months after the last&#xD;
             study drug administration for women, and 1 month for men.&#xD;
&#xD;
          -  Subject has known sensitivity to any of the products to be administered during the&#xD;
             study.&#xD;
&#xD;
          -  Subject has any kind of disorder that compromises the ability of the subject to give&#xD;
             written informed consent and/or comply with study procedures.&#xD;
&#xD;
          -  Any condition which in the investigator's opinion makes the subject unsuitable for&#xD;
             study participation&#xD;
&#xD;
          -  Subjects enrolled and dosed in phase 1b will be excluded from phase 2&#xD;
&#xD;
        Exclusion criteria for phase 1b and bevacizumab treatment (cohorts C, D and E) in phase 2&#xD;
&#xD;
          -  Subjects with central nervous system tumor involvement&#xD;
&#xD;
          -  Subjects with squamous NSCLC&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>July 26, 2007</study_first_submitted>
  <study_first_submitted_qc>July 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2007</study_first_posted>
  <disposition_first_submitted>March 2, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>March 2, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 30, 2016</disposition_first_posted>
  <last_update_submitted>June 10, 2016</last_update_submitted>
  <last_update_submitted_qc>June 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

